Lyra Therapeutics (LYRA) Operating Leases (2019 - 2025)
Quarterly Operating Leases fell 15.92% to $25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Dec 2025, down 15.92% year-over-year, with the annual reading at $25.4 million for FY2025, 15.92% down from the prior year.
Lyra Therapeutics' Operating Leases history spans 7 years, with the latest figure at $25.4 million for Q4 2025.
- Operating Leases came in at $25.4 million for Q4 2025, down from $26.7 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $33.4 million in Q1 2024 to a low of $3000.0 in Q2 2022.
- The 5-year median for Operating Leases is $4.9 million (2023), against an average of $14.1 million.
- Year-over-year, Operating Leases tumbled 99.68% in 2022 and then skyrocketed 162800.0% in 2023.
- Lyra Therapeutics' Operating Leases stood at $379000.0 in 2021, then soared by 75.99% to $667000.0 in 2022, then soared by 3115.44% to $21.4 million in 2023, then skyrocketed by 41.09% to $30.3 million in 2024, then decreased by 15.92% to $25.4 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Operating Leases are $25.4 million (Q4 2025), $26.7 million (Q3 2025), and $27.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.44 Mn |
| Sep 30, 2025 | 26.70 Mn |
| Jun 30, 2025 | 27.93 Mn |
| Mar 31, 2025 | 29.11 Mn |
| Dec 31, 2024 | 30.26 Mn |
| Sep 30, 2024 | 31.32 Mn |
| Jun 30, 2024 | 32.48 Mn |
| Mar 31, 2024 | 33.36 Mn |
| Dec 31, 2023 | 21.45 Mn |
| Sep 30, 2023 | 4.89 Mn |
| Mar 31, 2023 | 191,000.00 |
| Dec 31, 2022 | 667,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Dec 31, 2021 | 379,000.00 |
| Sep 30, 2021 | 656,000.00 |
| Jun 30, 2021 | 929,000.00 |
| Mar 31, 2021 | 1.20 Mn |
| Sep 30, 2020 | 1.71 Mn |
| Jun 30, 2020 | 1.96 Mn |
| Mar 31, 2020 | 2.19 Mn |
| Dec 31, 2019 | 2.43 Mn |